Edition:
India

Brainstorm Cell Therapeutics Inc (BCLI.OQ)

BCLI.OQ on NASDAQ Stock Exchange Capital Market

3.62USD
16 Aug 2019
Change (% chg)

-- (--)
Prev Close
$3.62
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
20,125
52-wk High
$4.50
52-wk Low
$2.95

Revenue & Earnings Per Share

    Revenue* Earnings Per Share**
FY 2019 Mar '19 0.00 -0.240
FY 2018 Dec '18 0.00 -0.260
Sep '18 0.00 -0.153
Jun '18 0.00 -0.158
Mar '18 0.00 -0.121
FY 2017 Dec '17 0.00 0.015
Sep '17 0.00 -0.128
Jun '17 0.00 -0.056
Mar '17 0.00 -0.096
 
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars

Consensus Estimates Analysis

  # of Estimates Mean High Low 1 Year Ago
SALES (in millions)
Quarter Ending Sep-19 1 0.00 0.00 0.00 1.50
Quarter Ending Dec-19 1 0.00 0.00 0.00 1.50
Year Ending Dec-19 1 0.00 0.00 0.00 6.00
Year Ending Dec-20 2 49.25 98.50 0.00 94.60
Earnings (per share)
Quarter Ending Sep-19 2 -0.17 -0.15 -0.18 -0.02
Quarter Ending Dec-19 2 -0.17 -0.17 -0.17 -0.03
Year Ending Dec-19 2 -0.69 -0.56 -0.82 -0.43
Year Ending Dec-20 2 -0.87 -0.85 -0.89 -0.08
Sales and Profit Figures in US Dollar (USD);

Valuation Ratios

Dividends

Growth Rates

Financial Strength

Profitability Ratios

Efficiency

Management Effectiveness

  1 Year 3 Year 5 Year
Sales % -- -- --
EPS (TTM) % -164.48 -- --
Dividend % -- -- --
Note: Units in Millions of US Dollars

Performance for Brainstorm Cell Therapeutics Inc

Period %
Actual
% vs.
S&P 500
Rank In
Industry
Industry
Rank
4 Week 3.29 0.42 71 --
13 Week 1.75 -1.15 71 --
26 Week 15.25 1.50 69 --
52 Week -3.77 -9.77 68 --
YTD 14.93 -4.78 59 --
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.

Institutional Holders

% Shares Owned: 11.46%
# of Holders: 43
Total Shares Held: 2,487,175
3 Mo. Net Change: 16,557
# New Positions: 2
# Closed Positions: 0
# Increased Positions: 3
# Reduced Positions: 0
# Net Buyers: 3
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.